Prospective, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Phase IIb Clinical Trial of the Pore-Forming Protein PRX302 for Targeted Treatment of Symptomatic Benign Prostatic Hyperplasia.
J. Urol., Nov (2012)
Relationships between Participants' International Prostate Symptom Score and BPH Impact Index Changes and Global Ratings of Change in a Trial of Phytotherapy for Men with Lower Urinary Tract Symptoms.
J. Urol., Sep (2012)
Reduction in Hospital Admission Rates Due to Post-Prostate Biopsy Infections After Augmenting Standard Antibiotic Prophylaxis.
J. Urol., Sep (2012)
Surgeon fatigue: impact of case order on perioperative parameters and patient outcomes.
J. Urol., Oct;188(4):1291-6 (2012)
Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: Long-term results from the combination of dutasteride and tamsulosin study.
Int. J. Urol., Nov;19(11):1031-1035 (2012)
Quantifying the contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial.
J. Urol., May;187(5):1732-8 (2012)
A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with Î±-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
Eur. Urol., May;61(5):994-1003 (2012)
Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Urology., Jan;79(1):5-11 (2012)
Association of overactive bladder and C-reactive protein levels. Results from the Boston Area Community Health (BACH) Survey.
BJU Int., Aug;110(3):401-7 (2012)
Best of the AUA Annual Meeting: Highlights From the 2011 American Urological Association Meeting, May 14-19, 2011, Washington, DC.
Rev Urol., 13(3):151-72 (2011)
Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy.
BJU Int., Jul;110(1):63-8 (2012)
Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.
J Sex Med., Jan;9(1):271-81 (2012)
Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving Î±-blocker treatment for lower urinary tract symptoms.
BJU Int., Jun;109(12):1831-40 (2012)
Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial.
JAMA., Sep;306(12):1344-51 (2011)
Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner.
J. Urol., Nov;186(5):2107-14 (2011)
The economic burden of prostate cancer.
BJU Int., Sep;108(6):806-13 (2011)
Validation of the modified American Urological Association symptom score.
J. Urol., Sep;186(3):945-8 (2011)
Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial.
J. Urol., Sep;186(3):965-70 (2011)
Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry.
J. Urol., Sep;186(3):971-6 (2011)
Methods of developing UWIN, the modified American Urological Association symptom score.
J. Urol., Sep;186(3):940-4 (2011)